関連ニュース

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardelyx To Contact Him Directly To Discuss Their Options If you purchased or acquired

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX).

New York, New York--(Newsfile Corp. - September 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ardelyx,

NEW YORK, Sept. 21, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) bet

Ardelyx NASDAQ: ARDX expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia

ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord. NEW YORK, Aug. 13, 2026 /PRNewswir

Ardelyx, Inc. remains a hold due to near-term execution uncertainty despite strong underlying demand for IBSRELA and a robust long-term opportunity. ARDX's Q2 revenue grew 31% YoY, driven by IBSRELA a